The Certified Clinical Research Associate designation is now formally recognized by TransCelerate Biopharma, Inc. as evidence of Good Clinical Practice training.
The Certified Clinical Research Associate (CCRA) designation is now formally recognized by TransCelerate Biopharma, Inc. (www.transceleratebiopharmainc.com) as evidence of Good Clinical Practice (GCP) training.
Clinical research professionals who hold a current CCRA designation may use that designation as evidence of GCP training while working at any of TransCelerate's 19 member companies, freeing them from any potential obligatory and/or redundant GCP training.
TransCelerate member companies include some of the world's largest pharmaceutical and biotechnology companies with research and development (R&D) operations, including Johnson & Johnson, AstraZeneca, Pfizer, Roche, GlaxoSmithKline, and more. TransCelerate launched in 2012 "to advance innovation in R&D, identify and solve common R&D challenges, and further improve patient safety."
"The CCRA designation shows both my employer and the sites I monitor that I have taken the extra step to be a professional," says Kathryn Kimmel, CCRA, CCRC, Senior Clinical Research Associate at PAREXEL International. "The CCRA designation states I have not only GCP training, but know International Conference on Harmonization and all standards that are needed for good clinical research to be performed at the site level and within my company. It establishes me as someone who has demonstrated the ability to apply this knowledge."
Recognition of the CCRA designation follows TransCelerate's January 2014 recognition of the Certified Clinical Research Coordinator (CCRC) and Certified Physician Investigator (CPI) designations as evidence of GCP training. In February 2014, TransCelerate also recognized ACRP GCP training courses as evidence of required GCP training.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.